HLTH 2026: Noom, Hims & Hers expand into booming peptide market

Hims & Hers peptide brand
Hims & Hers plans to initially sell five U.S.-compounded peptide and longevity treatments—Sermorelin, NAD+, Glutathione, Vitamin B12 and L-Carnitine, with plans to add more peptides and therapies over time. (Hims & Hers)

LAS VEGAS—Direct-to-consumer health companies Noom and Hims & Hers are making a play for the booming peptide market as the federal government loosens restrictions on compounded treatments.

The companies are betting that peptides could be the next big thing in consumer health. For Noom, the new peptide offering extends the company's business beyond weight loss into the broader longevity and wellness market. Hims & Hers signaled months ago that it was ready to tap into the multi-billion-dollar peptide market.

Federal policy shifts and U.S. Food and Drug Administration enforcement discretion around compounded peptides have opened new pathways for telehealth and compounding pharmacies. 

On Tuesday, Noom launched OpenRx as a separate peptide and preventive health brand. At launch, OpenRx offers two injectable options: sermorelin, a peptide frequently prescribed for muscle support, and NAD+, a coenzyme frequently prescribed for energy. OpenRx also offers two oral dissolvable tablet options: the first formulation combines the peptides PT-141 and oxytocin with tadalafil to support sexual health. The second ODT formulation is the peptide oxytocin to support intimacy. 

Noom says it plans to expand into other areas including recovery, muscle health, skin, gut health and sleep. Peptides are small pieces of protein that occur naturally in the body and help control functions such as growth, healing and appetite.

“Peptides are an important portion of the formulary of healthy aging,” Geoff Cook, CEO of Noom, said in a statement. “OpenRx enables our flagship Noom brand to deepen into cardiometabolic health while the new brand OpenRx supports patients with conditions too often neglected by traditional care models, like energy, muscle composition, skin health, sexual health, sleep, and recovery. Together, both brands support the same mission: to empower everyone, everywhere to live better longer – every day.”

Noom says every OpenRx prescription is written by a licensed clinician following an evaluation of the patient’s health history, goals and clinical appropriateness. Treatments are fulfilled through Noom’s U.S.-based pharmacy network, which operates under state boards of pharmacy oversight and adheres to USP compounding standards, the company said.

Noom is currently reviewing BPC-157 and TB-500 as part of its ongoing process of evaluating emerging treatments for inclusion in our formulary, Jeffrey Egler, M.D., Noom's chief medical officer, said in a statement. "Each therapy offered by OpenRx is selected because our clinical team and I believe it is appropriate for improving patient health. The process involves continuous monitoring of safety-related signals, gathering the judgment of our medical directors and the medical directors of affiliated clinical networks based on years of prescribing experience with the compounds in question, ensuring a compliant and stable supply chain, sourcing of active pharmaceutical ingredients, and setting up processes for compliance with state and federal adverse event reporting guidelines," Egler said.

Online health and wellness brand Hims & Hers announced earlier this month it planned to roll out a peptides business. As part of the company's new Peptides+ specialty, launched today, it plans to initially sell five U.S.-compounded peptide and longevity treatments—Sermorelin, NAD+, Glutathione, Vitamin B12 and L-Carnitine, with plans to add more peptides and therapies over time. 

The company also plans to offer U.S.-made BPC-157 and TB-500 "consistent with regulatory requirements," the company said.

A survey the company conducted in October of 2,000 adults found that more than half (55%) said they were interested in or curious about peptide therapies, and 40% of U.S. adults say they are interested or very interested in a telehealth offering of injectable prescription treatments, including peptides and other compounded treatments. Nearly 1 in 10 U.S. adults (9%) say they currently use peptides, not including FDA-approved peptides such as Ozempic, Wegovy and insulin, the survey found.

Peptides are in the spotlight due to the massive success of FDA-approved GLP-1 weight loss medications like Ozempic and Wegovy, which are peptide drugs. Wellness influencers and biohackers on social media are promoting other lab-made peptides for fast-tracked healing, anti-aging and muscle growth.

Health and Human Services Secretary Robert F. Kennedy Jr. has championed looser federal rules on trendy, unapproved peptide injections. In July, an FDA advisory committee recommended broader access to six unapproved peptides. The panel recommended adding these six substances to the Section 503A Bulks List, which would remove the restrictions on how they are produced by compounders, Fierce Pharma reported.

Stopping short of a formal declaration allowing their use, Kennedy has cleared the way for the compounding of six popular wellness peptides, Fierce Pharma reported. Under Kennedy’s "enforcement discretion policy" issued in late October, HHS will not take enforcement action against pharmacies, physicians and federal facilities compounding six specific peptides, assuming those parties meet certain specific qualifications. 

But medical experts have raised safety and clinical evidence questions around unapproved or experimental compounds. The American Medical Association (AMA) publicly opposes the Trump administration’s plan to make certain unapproved peptides more widely available for human use.

In a letter (PDF) to the Department of Health and Human Services (HHS), the AMA pushed back what it called a "rushed" decision to permit the compounding of certain peptides because they have not been approved for safe use by the FDA.

Unproven peptides may pose serious health risks, including allergic reactions, infections, hormonal imbalances and other unexpected side effects, according to the FDA website.

"We should not bypass the science and put patients at risk by making them guinea pigs for unapproved drugs," AMA President Willie Underwood III, M.D., said in a statement. "If these substances are safe and effective, the evidence should demonstrate that through the FDA’s rigorous review process."

Hims & Hers' peptide therapy program provides a "clinically guided, personalized plan" for consumers "backed by a licensed provider who understands these therapies," according to Anant Vinjamoori, M.D., chief medical officer of the Hims brand.

Hims & Hers wants to "set the standard" for peptide therapy and offer consistency in the quality of the products, Vinjamoori said in an interview on the sidelines of the HLTH conference this week.

"If you think about what we have to bring to the table with our scale and resources, I would argue there's no one better equipped to do it than us," Vinjamoori said.

Hims & Hers has invested in its supply chain and expanded its domestic manufacturing facilities. In 2025, the company acquired a Menlo Park peptide facility to run API validation and stability testing to support its specialized peptide offerings.

 "That's why we're investing in our supply chain and doing a lot of the hard work that, frankly, is not the fastest path to making these available. There are pharmacies that are already out there that are making these available, and there are companies out there that will simply just plug into those pharmacies and service patients. But there are inconsistencies," he noted.

Until now, getting these types of medications has often meant relying on unreliable and unregulated online sellers, or a high-cost longevity clinic, Hims & Hers executives said. Hims & Hers' peptides offering gives consumers more accessible care, "backed by real medical leadership and with consistent clinical oversight," the company said in a press release.

Hims & Hers believes its scale gives it an opportunity and responsibility to help build the evidence base around peptides, using growing patient interest not just to expand access but to better understand how the treatments can be used safely and effectively, Vinjamoori said.

Expanding into peptides fits with Hims & Hers' ongoing focus on personalized health, he noted. "We started with sexual health, moved on to hair loss, and then we've continued to broaden into other categories such as hormone replacement, GLP-1s, and now peptides, and many others to come. And the common theme in all of this is that we're talking about helping people accomplish a specific goal that they have. We're not talking about curing a disease or treating a disease per se," he said. "We're talking about, 'Hey, there's something you want to do in your life that you're not able to do right now. Let's help you figure out how we can put together a plan to help you accomplish that."

"This is a big part of the future of medicine itself," Vinjamoori added. "It's been the missing part of the equation, where we've been very focused on treating and responding to disease, but not as much, not just on prevention, but really on helping people use their health as an asset and as a tool to help them accomplish what they want in life."

With Hims & Hers' peptide therapy offering, consumers start with a clinical visit with a licensed provider that includes a comprehensive intake of health history and goals. The company said a licensed provider trained in peptide therapies assesses each individual and, if appropriate, tailors a personalized protocol to their needs. 

Hims & Hers treatments are compounded in the U.S. and dispensed directly by licensed, U.S. pharmacies regulated by state boards of pharmacy and "held to rigorous quality and safety standards," the company said.

The buzz around peptides ties into consumers' growing interest in taking control of their health "driven by the cultural zeitgeist moment," Vinjamoori told Fierce Healthcare.

"There's a variety of different factors that catalyze that. I think the COVID-19 pandemic catalyzed a lot of it for a variety of reasons. I think you see accelerations in biotechnology where people now see something like GLP-1s that can help with a problem that seemed intractable before. I think people are now interested in figuring out what is the range of solutions that could help me. I also think peptides represent something that has a lot of promise, a lot of excitement," he said.

"But there are also some cautions that we need to take as well. Something we think a lot about is how do we meet this moment of excitement and enthusiasm with some degree of rigor and guardrails," Vinjamoori said.

"It starts with the product itself. How do we ensure the quality? The compounds are of the highest quality and are compounded in the most rigorous way, made available in the most rigorous way. That's why we are trying to have as much oversight as we can into the full process of making these available," he said.

He asserted that informed consent and transparency with consumers are critical. "I've spent a lot of time with the team to make sure that we understand that people have this enthusiasm, but we need to make sure that they understand what they're getting into. There is a difference between this and FDA-approved therapies," he said.

"Sometimes people should try the standard of care before they engage with some of these things, and so we want to make sure we have these conversations with people openly and honestly. But at the same time, we also want to respect their choice," he added.

Hims & Hers Peptides+ is available with its Care+ program that gives customers access to twice-a-year lab testing to track their progress, unlimited support and ongoing check-ins from a dedicated care team. Customers can also message providers trained in peptide therapy 24/7 with any questions. The Hims Men’s panel includes at-home blood collection and access to lab tests that provide insights across 22 biomarkers, including testosterone, vitamin D, and cholesterol. The Hers Women’s panel tests 22 biomarkers across hormones, vitamins, and heart health.